Key Highlights

  • FY26 Revenue including other income increased 10% to AUD 21.4mn.
  • Branded B2C revenue more than doubled to AUD 13.7mn, representing about 65% of annual revenue.
  • EBITDA improved by AUD 5.8mn to positive AUD 0.6mn, while Operating Cash Flow turned positive at AUD 0.5mn.
  • ECS advanced international expansion through Germany, New Zealand and Poland.

ECS Botanics (ASX:ECS) delivered a material improvement in its FY26 financial and operating performance, moving to positive EBITDA and positive operating cash flow while continuing to expand its branded medicinal cannabis portfolio.

Revenue including other income rose 10% to AUD 21.4mn for the year ended 30 June 2026. EBITDA improved by AUD 5.8mn to positive AUD 0.6mn, compared with a AUD 5.2mn loss in FY25.

Branded Portfolio Drives Revenue Growth

The company's own-brand portfolio was a key contributor to the FY26 improvement. Branded B2C revenue increased 101% year on year to AUD 13.7mn and represented approximately 65% of annual revenue.

Independent prescription analytics from NostraData indicated that ECS branded volumes increased 18.1% over the six months to June 2026, compared with an estimated 15.8% decline across the broader market captured by the dataset.

OzSun became ECS's largest Brand by revenue during FY26. The company also expanded its portfolio with the launch of AVANI AVA in women's health and Gelonoidz #20, its first Australian-grown Terphogz product.

Profit and Cash Flow Improve

ECS reduced its loss before tax to AUD 1.0mn from AUD 6.9mn in FY25. The statutory result included approximately AUD 3.35mn of non-cash inventory and receivables impairments.

Excluding those non-cash impairments, ECS would have reported a positive pre-tax result of approximately AUD 2.3mn.

Net operating cash flow also improved by AUD 5.6mn, moving from an AUD 5.1mn outflow in FY25 to an AUD 0.5mn inflow in FY26.

Cultivation Efficiency Improves

FY26 was the first full year in which ECS benefited from much of its previous cultivation and infrastructure investment.

Outdoor trimmed flower Yield increased 12% to 3.1 tonnes, while production from the company's 26 Protective Cropping Enclosures increased 43% to 5.3 tonnes of untrimmed dried flower.

Average production cost per gram declined 33% across the PCE network and 44% for outdoor cultivation compared with FY25.

With the major infrastructure Investment program largely complete, ECS is shifting its focus towards utilisation, yields, product quality and returns from its existing asset base.

International Expansion Advances

ECS launched OzSun commercially in Germany in June through its Partnership with Nimbus Health, with the initial shipment selling out within weeks.

In New Zealand, the company dispatched its first commercial shipment of 1,000 units of 10THC:10CBD medicinal cannabis oil to NUBU Pharmaceuticals, which subsequently placed a repeat order.

In Poland, the regulator approved ECS's first medicinal cannabis product. Subject to final labelling review and customary Import requirements, the company expects commercial flower Supply to commence by the end of CY2026.

What Could Come Next for ECS Botanics (ASX:ECS)?

ECS enters FY27 focused on growing branded B2C sales in Australia, scaling OzSun in Germany, expanding export revenue and increasing cultivation efficiency.

The company also plans to expand its AVANI AVA and Terphogz portfolios. Following year end, ECS announced the planned Australian launch of two 2g OzSun all-in-one rosin blend inhalation products under a capital-efficient consignment arrangement.